Vaxcyte (PCVX) News Today $79.74 -2.73 (-3.31%) Closing price 04:00 PM EasternExtended Trading$80.44 +0.70 (+0.88%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $670,800.00 in StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $83.85, for a total value of $670,800.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at $9,180,820.35. This trade represents a 6.81 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.February 20 at 8:19 PM | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 SharesFebruary 20 at 5:10 AM | insidertrades.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Purchased by State of New Jersey Common Pension Fund DState of New Jersey Common Pension Fund D grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 13.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 44,901 shares of tFebruary 20 at 3:54 AM | marketbeat.comTimesSquare Capital Management LLC Boosts Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)TimesSquare Capital Management LLC lifted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 53.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 413,637 shares of the company's stock afteFebruary 19 at 6:37 AM | marketbeat.comVaxcyte (PCVX) Expected to Announce Earnings on TuesdayVaxcyte (NASDAQ:PCVX) will be releasing earnings after the market closes on Tuesday, February 25, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665623)February 18 at 4:37 AM | marketbeat.comBanque Pictet & Cie SA Sells 5,457 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Banque Pictet & Cie SA lowered its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 8.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 59,315 shares of the company's stockFebruary 15, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Grows Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Allspring Global Investments Holdings LLC lifted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 70.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 593,523 shares of the company's stock after buFebruary 14, 2025 | marketbeat.comVaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025February 12, 2025 | globenewswire.comNeedham & Company LLC Reiterates Buy Rating for Vaxcyte (NASDAQ:PCVX)Needham & Company LLC restated a "buy" rating and set a $14.00 price objective on shares of Vaxcyte in a research report on Tuesday.February 11, 2025 | marketbeat.comWCM Investment Management LLC Reduces Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)WCM Investment Management LLC reduced its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 48.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 72,094 shares of the company's stock after selling 68,February 10, 2025 | marketbeat.com12 Best Healthcare Stocks to Buy According to AnalystsFebruary 9, 2025 | insidermonkey.comVaxcyte SVP Mikhail Eydelman sells $450k in stockFebruary 8, 2025 | msn.comWhy Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy According to AnalystsFebruary 8, 2025 | msn.comabrdn plc Increases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)abrdn plc lifted its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 171.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 224,824 shares of the company's stock after buying an additional 141,9February 7, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Calamos Advisors LLCCalamos Advisors LLC cut its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 62.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,995 shares of the company's stock after selling 16,836February 6, 2025 | marketbeat.comVaxcyte advances second stage of Phase 2 study evaluating VAX-31February 5, 2025 | markets.businessinsider.comVaxcyte COO Jim Wassil sells $689,790 in stockFebruary 5, 2025 | msn.comVaxcyte advances to final stage in infant vaccine studyFebruary 5, 2025 | msn.comVaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in InfantsFebruary 5, 2025 | globenewswire.comVaxcyte, Inc. (NASDAQ:PCVX) COO Sells $689,760.00 in StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $86.22, for a total value of $689,760.00. Following the transaction, the chief operating officer now directly owns 205,695 shares in the company, valued at $17,735,022.90. This trade represents a 3.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.February 4, 2025 | marketbeat.comJennison Associates LLC Buys 9,121 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)Jennison Associates LLC raised its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 0.7% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,246,551 shares of the company's stock after purchasing an additional 9,February 4, 2025 | marketbeat.comChina Universal Asset Management Co. Ltd. Has $2.16 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)China Universal Asset Management Co. Ltd. lifted its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 23.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,428 shares of the company's sFebruary 1, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Receives Average Recommendation of "Buy" from BrokeragesVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has earned an average recommendation of "Buy" from the eight brokerages that are covering the stock, MarketBeat reports. Eight investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages thJanuary 31, 2025 | marketbeat.comVaxcyte to Present at the Guggenheim SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmJanuary 30, 2025 | globenewswire.comAnalysts Set Expectations for Vaxcyte FY2025 EarningsVaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Vaxcyte in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen anticipates that the company will post earnings of ($7.02) per share forJanuary 23, 2025 | marketbeat.comVaxcyte president and CFO sells shares worth $692,100January 22, 2025 | msn.comAndrew Guggenhime Sells 8,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $86.51, for a total transaction of $692,080.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,472,066.41. The trade was a 6.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.January 22, 2025 | marketbeat.comWhy Vaxcyte, Inc. (PCVX) Is One of the Best Russell 2000 Stocks to Invest in According to Analysts?January 18, 2025 | msn.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) Director Sells 6,250 Shares of StockJanuary 18, 2025 | insidertrades.comVaxcyte (NASDAQ:PCVX) Trading Up 7.8% - Should You Buy?Vaxcyte (NASDAQ:PCVX) Trading Up 7.8% - Time to Buy?January 17, 2025 | marketbeat.comTeri Loxam Sells 6,250 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) Director Teri Loxam sold 6,250 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the transaction, the director now directly owns 7,175 shares of the company's stock, valued at approximately $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.January 17, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Stock Price Up 7.8% - Still a Buy?Vaxcyte (NASDAQ:PCVX) Trading 7.8% Higher - Time to Buy?January 15, 2025 | marketbeat.comVaxcyte’s VAX-A1 Vaccine: A Promising Contender in the Global Fight Against Group A StrepJanuary 15, 2025 | markets.businessinsider.comLeerink Partnrs Forecasts Vaxcyte FY2029 EarningsVaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Investment analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of Vaxcyte in a note issued to investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger anticipates that the company will earn $2.42 per share for the yearJanuary 14, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Harbor Capital Advisors Inc.Harbor Capital Advisors Inc. grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 15.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 74,907 shares of the company's stock aJanuary 11, 2025 | marketbeat.com17,502 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Bought by Diversified Trust CoDiversified Trust Co purchased a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,502 shares of the company's stock, valued at approximatelJanuary 9, 2025 | marketbeat.comKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmJanuary 7, 2025 | prnewswire.comVaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Recommendation of "Buy" from BrokeragesVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) has been given an average rating of "Buy" by the eight research firms that are covering the stock, Marketbeat.com reports. Eight research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages thatJanuary 6, 2025 | marketbeat.comVaxcyte, Inc. (NASDAQ:PCVX) COO Sells $669,280.00 in StockVaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 8,000 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $83.66, for a total value of $669,280.00. Following the transaction, the chief operating officer now owns 205,695 shares of the company's stock, valued at approximately $17,208,443.70. This trade represents a 3.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.January 3, 2025 | marketbeat.comPrincipal Financial Group Inc. Has $6.02 Million Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)Principal Financial Group Inc. boosted its stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 186.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 52,702 shares of the company's stocJanuary 2, 2025 | marketbeat.comVaxcyte (NASDAQ:PCVX) Shares Down 5.8% - Here's WhyVaxcyte (NASDAQ:PCVX) Shares Down 5.8% - Here's What HappenedDecember 27, 2024 | marketbeat.comIs Vaxcyte, Inc. (PCVX) the Best Performing Biotech Stock in 2024?December 23, 2024 | msn.comVaxcyte’s Promising Pipeline and Strategic Positioning: A Buy Recommendation Amidst Market ChallengesDecember 22, 2024 | markets.businessinsider.comGoldman Sachs Initiates Coverage of Vaxcyte (PCVX) with Buy RecommendationDecember 21, 2024 | msn.comVaxcyte a new buy at Goldman Sachs on vaccine platform, pneumonia assetDecember 20, 2024 | msn.comVaxcyte initiated with a Buy at Goldman SachsDecember 20, 2024 | markets.businessinsider.comThe Goldman Sachs Group Begins Coverage on Vaxcyte (NASDAQ:PCVX)The Goldman Sachs Group began coverage on shares of Vaxcyte in a report on Friday. They set a "buy" rating and a $135.00 target price on the stock.December 20, 2024 | marketbeat.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells 8,000 Shares of StockDecember 20, 2024 | insidertrades.comKuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law FirmDecember 19, 2024 | globenewswire.com Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address PCVX Media Mentions By Week PCVX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PCVX News Sentiment▼1.080.60▲Average Medical News Sentiment PCVX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PCVX Articles This Week▼75▲PCVX Articles Average Week Get Vaxcyte News Delivered to You Automatically Sign up to receive the latest news and ratings for PCVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies argenx News Today BioNTech News Today Teva Pharmaceutical Industries News Today Summit Therapeutics News Today Genmab A/S News Today Intra-Cellular Therapies News Today Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Sarepta Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PCVX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
